• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Cannabis Stock Movers For June 17, 2024

    6/17/24 4:30:05 PM ET
    $CARA
    $CRBP
    $PMD
    $XXII
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CARA alert in real time by email

    GAINERS:

    • Maple Leaf Green World (OTC:MGWFF) shares closed up 40.83% at $0.03
    • Rocky Mountain High (OTC:RMHB) shares closed up 34.23% at $0.01
    • CordovaCann (OTC:LVRLF) shares closed up 28.19% at $0.07
    • Pharmadrug (OTC:LMLLF) shares closed up 25.16% at $0.02
    • MJ Holdings (OTC:MJNE) shares closed up 24.35% at $0.01
    • Psychemedics (NASDAQ:PMD) shares closed up 12.00% at $2.27
    • Auxly Cannabis Group (OTC:CBWTF) shares closed up 8.84% at $0.02
    • 1933 Industries (OTC:TGIFF) shares closed up 8.33% at $0.01
    • SOL Glb Inv (OTC:SOLCF) shares closed up 8.21% at $0.05
    • iAnthus Capital Hldgs (OTC:ITHUF) shares closed up 7.96% at $0.02
    • Zoned Props (OTC:ZDPY) shares closed up 6.23% at $0.65
    • Trulieve Cannabis (OTC:TCNNF) shares closed up 4.12% at $8.85
    • Cannabix Technologies (OTC:BLOZF) shares closed up 3.91% at $0.36
    • Green Thumb Industries (OTC:GTBIF) shares closed up 3.51% at $11.80

    LOSERS:

    • Elixinol Wellness (OTC:ELLXF) shares closed down 51.22% at $0.00
    • Cann Gr (OTC:CNGGF) shares closed down 45.00% at $0.03
    • Global Hemp Group (OTC:GBHPF) shares closed down 42.53% at $0.03
    • Cara Therapeutics (NASDAQ:CARA) shares closed down 22.97% at $0.25
    • CV Sciences (OTC:CVSI) shares closed down 22.80% at $0.06
    • 22nd Century Group (NASDAQ:XXII) shares closed down 19.17% at $0.67
    • Global Compliance (OTC:FUAPF) shares closed down 17.58% at $0.01
    • Corbus Pharmaceuticals (NASDAQ:CRBP) shares closed down 15.82% at $44.21
    • CNBX Pharmaceuticals (OTC:CNBX) shares closed down 14.89% at $0.01
    • CLS Holdings USA (OTC:CLSH) shares closed down 6.13% at $0.05
    • Charlottes Web Holdings (OTC:CWBHF) shares closed down 5.69% at $0.15
    • Nextleaf Solutions (OTC:OILFF) shares closed down 5.44% at $0.07
    • Leafbuyer Techs (OTC:LBUY) shares closed down 4.76% at $0.02
    • 4Front Ventures (OTC:FFNTF) shares closed down 3.93% at $0.09

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $CARA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CARA
    $CRBP
    $PMD
    $XXII

    CompanyDatePrice TargetRatingAnalyst
    Corbus Pharmaceuticals Holdings Inc.
    $CRBP
    7/30/2025$28.00Buy
    B. Riley Securities
    Corbus Pharmaceuticals Holdings Inc.
    $CRBP
    2/28/2025Outperform
    William Blair
    Corbus Pharmaceuticals Holdings Inc.
    $CRBP
    12/2/2024Overweight
    Piper Sandler
    Corbus Pharmaceuticals Holdings Inc.
    $CRBP
    7/30/2024$85.00Outperform
    Wedbush
    Corbus Pharmaceuticals Holdings Inc.
    $CRBP
    7/22/2024$80.00Buy
    H.C. Wainwright
    Corbus Pharmaceuticals Holdings Inc.
    $CRBP
    6/26/2024$85.00Buy
    B. Riley Securities
    Cara Therapeutics Inc.
    $CARA
    6/13/2024$6.00 → $1.00Buy → Hold
    Stifel
    Cara Therapeutics Inc.
    $CARA
    6/13/2024$10.00 → $1.00Buy → Hold
    Canaccord Genuity
    More analyst ratings

    $CARA
    $CRBP
    $PMD
    $XXII
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Powell Anderson Capital Partners Llc bought $305,439 worth of shares (159,700 units at $1.91) (SEC Form 4)

    4 - PSYCHEMEDICS CORP (0000806517) (Issuer)

    12/17/24 8:29:49 PM ET
    $PMD
    Medical Specialities
    Health Care

    Large owner Powell Anderson Capital Partners Llc bought $231,849 worth of shares (86,991 units at $2.67) (SEC Form 4)

    4 - PSYCHEMEDICS CORP (0000806517) (Issuer)

    12/12/24 8:41:51 PM ET
    $PMD
    Medical Specialities
    Health Care

    Director Kamin Peter bought $3,312,823 worth of shares (1,409,712 units at $2.35) (SEC Form 4)

    4 - PSYCHEMEDICS CORP (0000806517) (Issuer)

    12/5/24 6:05:08 PM ET
    $PMD
    Medical Specialities
    Health Care

    $CARA
    $CRBP
    $PMD
    $XXII
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Medical Officer Smethurst Dominic sold $26,575 worth of shares (3,285 units at $8.09), decreasing direct ownership by 3% to 95,887 units (SEC Form 4)

    4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)

    2/4/26 4:25:42 PM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Operating Officer Hodgson Ian sold $19,537 worth of shares (2,415 units at $8.09), decreasing direct ownership by 4% to 51,927 units (SEC Form 4)

    4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)

    2/4/26 4:24:39 PM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Operating Officer Hodgson Ian was granted 28,365 shares, increasing direct ownership by 109% to 54,342 units (SEC Form 4)

    4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)

    1/16/26 4:30:03 PM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CARA
    $CRBP
    $PMD
    $XXII
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    December 23, 2021 - FDA Authorizes Marketing of Tobacco Products that Help Reduce Exposure to and Consumption of Nicotine for Smokers Who Use Them

    For Immediate Release: December 23, 2021 Today, the U.S. Food and Drug Administration authorized the marketing of 22nd Century Group Inc.’s “VLN King” and “VLN Menthol King” combusted, filtered cigarettes as modified risk tobacco products (MRTPs), which help reduce exposure to, and consumption of, nicotine for smokers who use them. These are the first combusted cigarettes to be authorized as MRTPs and the second

    12/23/21 9:06:12 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    FDA Approval for KORSUVA issued to CARA THERAPEUTICS INC

    Submission status for CARA THERAPEUTICS INC's drug KORSUVA (ORIG-1) with active ingredient DIFELIKEFALIN has changed to 'Approval' on 08/23/2021. Application Category: NDA, Application Number: 214916, Application Classification: Type 1 - New Molecular Entity

    8/24/21 12:36:58 PM ET
    $CARA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CARA
    $CRBP
    $PMD
    $XXII
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Corbus Pharmaceuticals Holdings Inc.

    SCHEDULE 13G/A - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Subject)

    2/10/26 1:14:49 PM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    22nd Century Group Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Material Modification to Rights of Security Holders, Financial Statements and Exhibits

    8-K - 22nd Century Group, Inc. (0001347858) (Filer)

    1/22/26 8:00:48 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    Corbus Pharmaceuticals Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Filer)

    1/12/26 7:26:40 AM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CARA
    $CRBP
    $PMD
    $XXII
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Corbus Pharmaceuticals to Present at the 36th Annual Oppenheimer Healthcare Life Sciences Conference

    NORWOOD, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP), a clinical-stage company focused on oncology and obesity, today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will present a corporate overview and attend investor meetings at the 36th Annual Oppenheimer Healthcare Life Sciences Conference, to be held virtually February 25-25, 2026. 36th Annual Oppenheimer Healthcare Life Sciences Conference Format: Virtual presentation and one-on-one investor meetings Date: February 25, 2026 Presentation Time: 3:20pm Eastern TimeWebcast Link: Click Here About CorbusCorbus Pharmaceuticals Holdings, Inc. is a clinical stage oncolog

    2/12/26 8:00:00 AM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    22nd Century CEO & Chairman Larry Firestone Provides 2025 Year-in-Review Letter to Stockholders

    MOCKSVILLE, N.C., Jan. 15, 2026 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), the only tobacco products company that has for 27 years led and continues to lead the fight against the harms of smoking driven by nicotine addiction, today issued the following letter to stockholders from Lawrence Firestone, the Chief Executive Officer of 22nd Century Group, Inc.:  2025 Year-in-Review Shareholder Letter Dear Shareholders, 2025 was a pivotal year for 22nd Century Group, Inc. as we exited our multi-year restructuring, began advancing our strategic initiatives, strengthened our financial foundation, and reinforced our leadership position in tobacco harm reduction. In a complex regu

    1/15/26 9:00:00 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    22nd Century to Participate in the Needham Annual Growth Conference January 16, 2026

    MOCKSVILLE, N.C., Jan. 12, 2026 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), the only tobacco products company that has for 27 years led and continues to lead the fight against the harms of smoking driven by nicotine addiction, today announced that Larry Firestone, Chief Executive Officer, and Dan Otto, Chief Financial Officer, will present as part of the Needham Growth Conference taking place on Friday, January 16, 2026. The management team will be available for virtual one-on-one meetings. Investors interested in booking meetings can register for the conference and arrange a time through their Needham representative, or the Company's investor relations at investorrelation

    1/12/26 4:30:00 PM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    $CARA
    $CRBP
    $PMD
    $XXII
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    B. Riley Securities resumed coverage on Corbus Pharma with a new price target

    B. Riley Securities resumed coverage of Corbus Pharma with a rating of Buy and set a new price target of $28.00

    7/30/25 8:22:15 AM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    William Blair initiated coverage on Corbus Pharma

    William Blair initiated coverage of Corbus Pharma with a rating of Outperform

    2/28/25 7:22:12 AM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Piper Sandler initiated coverage on Corbus Pharma

    Piper Sandler initiated coverage of Corbus Pharma with a rating of Overweight

    12/2/24 9:55:40 AM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CARA
    $CRBP
    $PMD
    $XXII
    Leadership Updates

    Live Leadership Updates

    View All

    22nd Century Announces First Shipments of Pinnacle VLN® Products to Top 5 C-Store Chain Locations Across 12 States

    Pinnacle VLN® from 22nd Century Gains 2nd Early Adopter to Join Popular Pinnacle Branded Conventional Cigarette Products Already Sold at Top-5 U.S. C-Store Chain MOCKSVILLE, N.C., Aug. 04, 2025 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), the only tobacco products company that has for 27 years led and continues to lead the fight against the harms of smoking driven by nicotine addiction, today announced the first shipments of its new Pinnacle VLN® Gold and Pinnacle VLN® Menthol reduced nicotine content cigarettes into distribution. These initial Pinnacle VLN® shipments will support a sales launch expected on September 1, 2025 at almost 1,000 locations across 12 states for a

    8/4/25 8:00:00 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair

    NORWOOD, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP), a clinical-stage company focused on oncology and obesity, today announced the appointment of Rachelle Jacques as Chair of its Board of Directors, effective May 15. She succeeds Alan Holmer, who will remain on the Board. "We thank Alan for his over ten years of dedicated service as founding Chair of the Corbus Board," said Yuval Cohen, Ph.D., Chief Executive Officer of Corbus. "Rachelle is a seasoned biopharmaceutical executive, and we have greatly benefitted from her innovative and strategic thinking as a Board member.  We look forward to following her vision and continued leadership as we

    5/19/25 8:00:00 AM ET
    $AKTX
    $CRBP
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Corbus Pharmaceuticals Strengthens Board of Directors with Appointment of Winston Kung

    NORWOOD, Mass., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), today announced the appointment of Winston Kung to its Board of Directors. The appointment was effective as of August 16, 2024. Mr. Kung will also chair the Audit Committee. "With this track record of success in both the pharma industry and on Wall Street, Winston has earned a well-deserved reputation for his leadership and financial acumen," said Alan F. Holmer, Chairman of the Corbus Board of Directors. "We are delighted to welcome someone of Winston's stature and expertise to our Board and we look forward to his insights and guidance." "Winston brings an e

    8/20/24 8:00:00 AM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CARA
    $CRBP
    $PMD
    $XXII
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Psychemedics Corporation

    SC 13D/A - PSYCHEMEDICS CORP (0000806517) (Subject)

    12/12/24 5:15:40 PM ET
    $PMD
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by Psychemedics Corporation

    SC 13G/A - PSYCHEMEDICS CORP (0000806517) (Subject)

    12/6/24 9:18:20 PM ET
    $PMD
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13D/A filed by Psychemedics Corporation

    SC 13D/A - PSYCHEMEDICS CORP (0000806517) (Subject)

    12/5/24 6:04:48 PM ET
    $PMD
    Medical Specialities
    Health Care

    $CARA
    $CRBP
    $PMD
    $XXII
    Financials

    Live finance-specific insights

    View All

    Corbus Pharmaceuticals Reports Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity Demonstrating Favorable Safety Profile and Emerging Evidence of Weight Loss

    CRB-913 was safe and well-tolerated across all doses studiedDaily neuropsychiatric assessments using CSSRS, PHQ-9, and GAD-7 were negative for all participantsA placebo-adjusted mean weight loss of 2.9% was observed at Day 14 in a dedicated cohort of people with obesity (n=12)A 12-week dose-finding study in people with obesity initiated with completion expected in summer 2026Company to host conference call and live webcast today at 8:00 am ET NORWOOD, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP), a clinical-stage company focused on oncology and obesity, today announced the completion of the single ascending dose (SAD) and multiple ascending d

    12/11/25 7:00:00 AM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Corbus Pharmaceuticals to Report Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity on Thursday, December 11, 2025

    NORWOOD, Mass., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP), a clinical stage company focused on oncology and obesity, announced the Company's plan to release results of its Phase 1a single ascending dose (SAD) and multiple ascending dose (MAD) study of CRB-913 prior to the market open on Thursday, December 11, 2025. Corbus will host a conference call and live webcast the same day at 8:00 am ET to review and discuss the Phase 1a data. To register for the webcast, click here . A replay will be available on the Corbus website. About CRB-913CRB-913 is an oral small molecule inverse agonist of the G-protein Coupled Receptor (GPCR) cannabinoid type-1 (

    12/10/25 4:01:00 PM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    22nd Century Group Reports Third Quarter 2025 Financial Results

    Significant Balance Sheet Improvement - Debt Free, Receives $9.5 Million in Non-Dilutive Cash VLN® and Partner VLN® Launches Underway, Rapidly Expanding Store Counts and Availability MOCKSVILLE, N.C., Nov. 04, 2025 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), the only tobacco products company that has for 27 years led and continues to lead the fight against the harms of smoking driven by nicotine addiction, today announced results for the third quarter-ended September 30, 2025, and provided an update on recent business highlights. "The third quarter represents the launch point for a full pivot to a branded products strategy that will drive our future. Multiple brands of o

    11/4/25 6:00:00 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care